# Duvelisib to Combat COVID-19

> **NCT04372602** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 28 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Duvelisib
- **PROCEDURE:** Peripheral blood draw
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04372602
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-12
- **Primary completion:** 2022-02-06
- **Final completion:** 2022-03-02
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04372602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04372602, "Duvelisib to Combat COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04372602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*